Cullen Frost Bankers Inc. Has $377,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Cullen Frost Bankers Inc. increased its position in DexCom, Inc. (NASDAQ:DXCM) by 123.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,851 shares of the medical device company’s stock after buying an additional 2,679 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in DexCom were worth $377,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Forvis Mazars Wealth Advisors LLC increased its stake in shares of DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after buying an additional 118 shares during the period. Principal Securities Inc. increased its position in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after purchasing an additional 135 shares during the period. Crossmark Global Holdings Inc. increased its position in DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after purchasing an additional 182 shares during the period. GPS Wealth Strategies Group LLC increased its position in DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after purchasing an additional 185 shares during the period. Finally, Peterson Wealth Services increased its position in DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock valued at $236,000 after purchasing an additional 201 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock worth $3,309,794 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DXCM shares. Wells Fargo & Company increased their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and increased their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Finally, Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Price Performance

Shares of DXCM opened at $77.84 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The business’s fifty day moving average is $84.83 and its 200 day moving average is $76.99. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a market cap of $30.42 billion, a P/E ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.